Cold-Tolerant Plants
    414.
    发明申请
    Cold-Tolerant Plants 有权
    耐寒植物

    公开(公告)号:US20120036597A1

    公开(公告)日:2012-02-09

    申请号:US13197187

    申请日:2011-08-03

    CPC classification number: C12N15/8273

    Abstract: Disclosed are chill- or cold-tolerant plants and methods of making the plants. Also disclosed are methods for identifying a plant that is tolerant to chill.

    Abstract translation: 公开了冷或冷耐受植物和制造植物的方法。 还公开了用于鉴定耐寒的植物的方法。

    Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus amboinicus extracts
    415.
    发明授权
    Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus amboinicus extracts 有权
    用于治疗炎症和与炎症有关的疾病的组合物和方法,由Plectranthus amboinicus提取物

    公开(公告)号:US08105636B2

    公开(公告)日:2012-01-31

    申请号:US12212607

    申请日:2008-09-17

    CPC classification number: A61K36/53 A61K31/215 A61K31/235

    Abstract: The crude extract of Plectranthus Amboinicus (PA) has anti-inflammatory effects and can inhibit AP-1 binding in vitro. The incubation with PA crude extract resulted in significant inhibition of the LPS-induced expression of IL-6, IL-12, MCP-1, and RANTES in HUVEC cells. After the crude extract was further fractionated using preparative HPLC, fraction 8, 9, 10 and 11 were identified to inhibit the AP-1 binding activity. The active component of fraction 8 is Mena 987; fraction 9 is Mena 998; fraction 10 is Mena 9102; and fraction 11 is rosmarinic acid and the synthetic rosmarinic acid analogues. Other compounds showed inhibitory activities as well. These compounds have inhibitory effects on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression or activities of AP-1 are involved.

    Abstract translation: 芍药(Plectranthus Amboinicus,PA)的粗提物具有抗炎作用,能体外抑制AP-1结合。 与PA粗提取物的孵育导致LPS诱导的HUVEC细胞中IL-6,IL-12,MCP-1和RANTES的表达的显着抑制。 在使用制备型HPLC进一步分馏粗提取物后,鉴定出8,9,10和11级分抑制AP-1结合活性。 级分8的活性组分是Mena 987; 9级是Mena 998; 级分10是Mena 9102; 并且级分11是迷迭香酸和合成的迷迭香酸类似物。 其他化合物也显示抑制活性。 这些化合物对AP-1活性具有抑制作用,可用作涉及AP-1过度表达或活性的疾病的预防或治疗剂。

    Imaging of Biological Structures
    416.
    发明申请
    Imaging of Biological Structures 有权
    生物结构成像

    公开(公告)号:US20110288409A1

    公开(公告)日:2011-11-24

    申请号:US13195201

    申请日:2011-08-01

    Abstract: Images of blood vessels of a body are obtained by injecting a refraction enhancement contrast agent into the blood vessels to increase a difference in refractive indices of the blood vessels and surrounding material. The blood vessels are irradiated with a penetrating radiation, and an image of the blood vessels is generated based on detected radiation. The image has visible edge enhancement features indicating boundaries of the blood vessels.

    Abstract translation: 通过将折射增强造影剂注射到血管中以增加血管和周围材料的折射率差异来获得身体血管的图像。 用穿透性辐射照射血管,并且基于检测到的辐射产生血管的图像。 该图像具有指示血管边界的可见边缘增强特征。

    Risk assessment for adverse drug reactions

    公开(公告)号:US07964351B2

    公开(公告)日:2011-06-21

    申请号:US12123700

    申请日:2008-05-20

    CPC classification number: C12Q1/6881 C12Q1/6883 C12Q2600/156 G01N33/94

    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

Patent Agency Ranking